Document is current
Any future updates will be listed below
-
Authors
Tsai, Chiou-Tsun https://orcid.org/0009-0007-7505-7107
Ibanez-Vega, Jorge
Yin, Pan
Teis, Robert
Watanabe, Norihiro
Honda, Tadahiro
Valkov, Mikhail
Chockley, Peter J. https://orcid.org/0000-0002-5181-2696
Madrigal, Lourdes Asenath Jimenez
Krenciute, Giedre https://orcid.org/0000-0003-4335-0644
Mamonkin, Maksim https://orcid.org/0000-0001-7178-8163
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP210158)
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 27 October 2025
First Online: 4 February 2026
Competing interests
: M.M. is a co-founder with equity and an independent director at March Biosciences. M.M. receives fees from Allogene, Beam Therapeutics, Fate Therapeutics, March Biosciences, and Curie.bio. M.M. receives research support from Fate Therapeutics and March Biosciences and honoraria from Amgen and Galapagos NV and serves on the advisory board of NKILT Therapeutics and March Biosciences. M.M., N.W., G.K. and C.T.T. have patent applications in the field of engineered cell therapies. An up to date declaration of interests for the listed authors can be found at . The remaining authors declare no competing interests.
